These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 3807263)

  • 21. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study.
    Mittermayr M; Margreiter J; Velik-Salchner C; Klingler A; Streif W; Fries D; Innerhofer P
    Br J Anaesth; 2005 Sep; 95(3):310-6. PubMed ID: 16024582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental study of the heparin antagonist protamine chloride].
    Efimov VS
    Farmakol Toksikol; 1968; 31(5):601-4. PubMed ID: 5707736
    [No Abstract]   [Full Text] [Related]  

  • 23. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin neutralization by recombinant platelet factor 4 and protamine.
    Levy JH; Cormack JG; Morales A
    Anesth Analg; 1995 Jul; 81(1):35-7. PubMed ID: 7598278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the effect of varying protamine-to-heparin ratio on coagulation in vitro.
    Ho LTS; McVey MJ; Kuiper GJAJM; Gross PL; Karkouti K
    Br J Anaesth; 2021 Oct; 127(4):e128-e130. PubMed ID: 34334192
    [No Abstract]   [Full Text] [Related]  

  • 27. The effects of protamine sulfate on clot formation time and clot strength thromboelastography variables for canine blood samples.
    Bailey CJ; Koenigshof AM
    Am J Vet Res; 2014 Apr; 75(4):338-43. PubMed ID: 24669916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine.
    Byun Y; Chang LC; Lee LM; Han IS; Singh VK; Yang VC
    ASAIO J; 2000; 46(4):435-9. PubMed ID: 10926141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of regulating blood clotting with heparin and its antagonists on mast cells].
    Efimov VS; Rozkin MIa; Poberiĭ IA; Lindner DP
    Farmakol Toksikol; 1981; 44(1):80-5. PubMed ID: 7262304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine].
    Doutremepuich C; Bonini F; Masse A; Bousquet F; Bayrou B; Toulemonde F
    Ann Pharm Fr; 1986; 44(1):65-72. PubMed ID: 3777780
    [No Abstract]   [Full Text] [Related]  

  • 32. In-vitro and ex-vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin.
    Falkon L; Garí M; Gich I; Fontcuberta J
    Thromb Res; 1998 Jan; 89(2):79-83. PubMed ID: 9630311
    [No Abstract]   [Full Text] [Related]  

  • 33. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.
    Racanelli A; Fareed J
    Thromb Res; 1992 Nov; 68(3):211-22. PubMed ID: 1471069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralisation of heparan sulphate and low molecular weight heparin by protamine.
    Hubbard AR; Jennings CA
    Thromb Haemost; 1985 Feb; 53(1):86-9. PubMed ID: 3158095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
    Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Protamine complexes with antithrombin III and heparin].
    Roszkowska W; Worowski K
    Acta Haematol Pol; 1982; 13(1-2):25-8. PubMed ID: 7180353
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro and in vivo characterization of a reversible synthetic heparin analog.
    Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
    Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation.
    Ni Ainle F; Preston RJ; Jenkins PV; Nel HJ; Johnson JA; Smith OP; White B; Fallon PG; O'Donnell JS
    Blood; 2009 Aug; 114(8):1658-65. PubMed ID: 19531655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
    Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
    AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.